BioStock: Chordate Medical’s CEO on the marketing and sales plans

2022 is expected to be a very important and exciting year for medtech company Chordate Medical, according to CEO Anders Weilandt's statement in the year-end report. The company is fully committed on pursuing the market plan for 2022, for both the migraine and the rhinitis treatments, but with stronger focus on migraine. They also aim to add one or more new markets during the year. BioStock contacted Weilandt to find out more about the marketing plans and his expectations for sales in 2022.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/chordate-medicals-ceo-on-the-marketing-and-sales-plans/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se